Alendronate (Fosamax) During Pregnancy and Lactation: What the Evidence Actually Shows

How Alendronate Works and Why the Bone Half-Life Matters

Alendronate is a nitrogen-containing bisphosphonate that binds tightly to hydroxyapatite on bone surfaces and gets internalized by osteoclasts during resorption. Once inside the osteoclast, it inhibits farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. This blocks protein prenylation, disrupts the osteoclast cytoskeleton, and triggers apoptosis [1].

The clinical result is a net reduction in bone turnover. In the Fracture Intervention Trial (FIT, N=2,027), alendronate 5-10 mg/day reduced radiographic vertebral fractures by 47% over 3 years compared to placebo in postmenopausal women with existing vertebral fractures [2]. That efficacy is well established. The pharmacokinetic property that complicates reproductive safety, though, is the drug's skeletal residence time.

Bisphosphonates incorporate into the bone matrix during mineralization. They remain sequestered there until that bone is resorbed. Estimates of the terminal half-life of alendronate in human bone range from roughly 10 to 12 years [3]. During pregnancy, maternal bone turnover accelerates to supply calcium to the developing fetus, especially in the third trimester. This raises a theoretical concern: could previously deposited alendronate re-enter the circulation in pharmacologically relevant concentrations during pregnancy, even years after the last dose?

That question has no definitive answer. But it is the central pharmacokinetic issue that distinguishes bisphosphonates from most other drugs when counseling women of childbearing age.

What the FDA Label Says

The original Fosamax label assigned pregnancy category C under the pre-2015 FDA system. That designation meant animal reproduction studies showed adverse effects on the fetus, and no adequate, well-controlled studies existed in pregnant women [4]. The drug should be used during pregnancy "only if the potential benefit justifies the potential risk to the fetus."

Since the 2015 Pregnancy and Lactation Labeling Rule (PLLR, also called the "final rule"), the FDA has moved toward narrative summaries rather than letter categories. The current alendronate label states there are no data on use in pregnant women, describes the animal findings, and notes the risk of fetal harm based on the mechanism of action and animal data [4].

The label also specifically warns prescribers that because bisphosphonates incorporate into bone and release over time, "there is a theoretical risk of fetal harm (e.g., skeletal and other abnormalities) when a woman becomes pregnant after completing a course of bisphosphonate therapy" [4]. This language is notable because it extends the warning window beyond active drug use.

Animal Reproductive Toxicity Data

The preclinical data come primarily from rat and rabbit developmental toxicity studies conducted by Merck during the original drug development program. These studies are summarized in the FDA label and have been reviewed in secondary analyses [5].

In pregnant rats given oral alendronate at doses of 1, 3, or 10 mg/kg/day during organogenesis, the following was observed: at 10 mg/kg/day (roughly 10 times the human dose of 40 mg/day on a mg/m² basis), there was incomplete fetal ossification of vertebral, skull, and sternal bones. Maternal toxicity, including hypocalcemia, was present at this dose as well. At 3 mg/kg/day, decreased body weight gain occurred. The no-observed-adverse-effect level (NOAEL) was 1 mg/kg/day.

Peripartum dosing in rats revealed a different risk. At doses ≥1 mg/kg/day during late gestation, dystocia (obstructed labor) occurred, attributed to maternal hypocalcemia. This resulted in higher pup mortality.

In rabbits, no fetal effects were seen at doses up to 35 mg/kg/day, though maternal toxicity (weight loss, reduced food consumption) was present at that dose.

The animal data raise two distinct concerns: direct fetal skeletal effects at supratherapeutic doses and maternal calcium disruption affecting delivery. Neither finding has been confirmed in humans, but neither has been ruled out.

Human Pregnancy Exposure Data

No randomized controlled trials of alendronate in pregnant women exist, and none are expected. The human evidence consists entirely of case reports, small case series, and data from inadvertent exposures reported to manufacturers or registries.

The most cited systematic review is by Stathopoulos et al. (2011), which compiled data on bisphosphonate-exposed pregnancies across all agents in the class [6]. Among roughly 78 cases of bisphosphonate exposure before or during pregnancy (including alendronate, pamidronate, etidronate, and others), there was no consistent pattern of congenital malformations. Transient neonatal hypocalcemia was reported in a small number of cases, mostly with intravenous bisphosphonates.

A later review by Green et al. (2014) examined pregnancy outcomes after preconception bisphosphonate exposure and similarly found no statistically significant increase in major malformations, miscarriage, or preterm birth compared to background population rates [7]. The authors cautioned, however, that the total sample size remained far too small to detect modest increases in rare outcomes.

Several individual case reports have documented healthy live births after first-trimester alendronate exposure, with normal neonatal calcium levels and no skeletal abnormalities at birth [8]. These reports are reassuring but carry the inherent limitations of uncontrolled observations with short follow-up.

The bottom line: the existing human data do not show a clear signal of harm, but the evidence is insufficient to establish safety. The numbers are too small to exclude a 2-3 fold increase in any specific malformation.

Preconception Counseling and the Washout Question

One of the most common clinical questions is how long a woman should stop alendronate before attempting conception. There is no consensus guideline.

The American College of Obstetricians and Gynecologists (ACOG) does not provide a specific washout duration for bisphosphonates. The Endocrine Society's 2019 clinical practice guideline on osteoporosis management acknowledges the concern but does not name a specific interval [9]. Some experts have suggested 6 to 12 months, reasoning that serum drug levels become undetectable within days of stopping the oral formulation, and that a period of drug-free bone turnover may reduce the theoretical circulating reservoir.

The problem with this reasoning is that it addresses plasma clearance but not the skeletal depot. Alendronate plasma half-life is approximately 72 hours. The drug is effectively undetectable in blood within a week of stopping. But the skeletal half-life, as noted, is a decade or longer [3]. No washout period will meaningfully deplete the bone-bound drug.

A practical approach, supported by several expert opinion papers, involves three steps:

1. Discontinue alendronate before conception, ideally at least one menstrual cycle prior
2. Confirm adequate vitamin D (target 25(OH)D ≥30 ng/mL) and calcium intake (1,000-1,200 mg/day)
3. Monitor serum calcium in the first trimester and neonatal period

This approach prioritizes what is modifiable (active drug exposure, nutritional cofactors) while acknowledging that the bone-stored drug cannot be extracted.

Alendronate and Breastfeeding

Data on alendronate excretion into human breast milk are absent. The FDA label states that it is not known whether the drug is present in human milk [4].

Pharmacokinetic reasoning offers some reassurance. Alendronate has an oral bioavailability of only 0.64% under fasting conditions and even less when taken with food [1]. If the drug were present in breast milk, the infant would absorb a very small fraction of whatever concentration appeared. Bisphosphonates also bind calcium avidly. Breast milk contains substantial calcium, which would likely chelate any free bisphosphonate and further reduce absorption.

Against this reasoning, though, is the absence of measured data. No study has quantified alendronate concentrations in human milk. The LactMed database maintained by the National Library of Medicine lists bisphosphonates as having insufficient data to assess infant risk during breastfeeding [10].

Given this uncertainty, most experts recommend against breastfeeding during active alendronate therapy. For women who took alendronate before pregnancy and have stopped the drug, breastfeeding is generally not discouraged, since active plasma levels should be negligible by the time of delivery.

Comparing Alendronate to Other Bisphosphonates in Pregnancy

All bisphosphonates share the same general concern: bone-matrix incorporation with long skeletal half-lives and limited human reproductive data. There are, however, some differences worth noting.

Intravenous bisphosphonates (zoledronic acid, pamidronate) achieve higher peak plasma concentrations and deliver larger doses to bone per infusion than weekly oral alendronate. The case reports of neonatal hypocalcemia have more frequently involved IV agents [6]. Whether this reflects higher fetal exposure or simply ascertainment bias (IV bisphosphonates are used in more severe disease) is unclear.

Risedronate and ibandronate, the other oral bisphosphonates used for osteoporosis, share identical FDA pregnancy labeling language. No agent in the class has enough human data to be considered safer than another during pregnancy.

Denosumab, the RANK-ligand inhibitor, is a biologic with a different pharmacokinetic profile. It does not accumulate in bone, and its effects on bone turnover are reversible within 6 to 12 months of the last dose. Animal data with denosumab (studied via the analogous molecule in cynomolgus monkeys) showed increased stillbirth and postnatal mortality at high doses [11]. Denosumab is also classified as pregnancy category X (or "contraindicated" in PLLR format). So it is not a safer alternative.

For women of childbearing age who need osteoporosis treatment, the decision is challenging. Options include short courses of bisphosphonates with a planned preconception washout, teriparatide (which is pregnancy category C and has its own concerns in animal data), or non-pharmacologic management with calcium, vitamin D, and weight-bearing exercise if the fracture risk is not imminent.

Monitoring Recommendations If Exposure Occurs

When a woman discovers she is pregnant while taking alendronate or shortly after stopping, several monitoring steps are appropriate.

First, stop the drug immediately. Ongoing first-trimester exposure should be minimized, though the fetus-critical window for skeletal effects is weeks 5 through 12 of gestation, and most women on weekly alendronate will have taken only 1 to 3 doses during that interval.

Second, check maternal serum calcium, phosphorus, and 25-hydroxyvitamin D. Maternal hypocalcemia, the mechanism of harm in animal models, is detectable and treatable. Oral calcium and vitamin D supplementation should be optimized.

Third, consider a detailed fetal anatomy ultrasound at 18 to 20 weeks. There is no validated protocol for bisphosphonate-specific fetal screening, but a standard anatomic survey will assess long-bone length and skeletal mineralization. Gross defects in ossification would be visible.

Fourth, check neonatal serum calcium within 48 hours of delivery. Transient neonatal hypocalcemia has been reported in a small number of bisphosphonate-exposed pregnancies and is treatable with calcium supplementation if detected.

These steps do not guarantee detection of all potential harms. They represent a reasonable approach given the limited data, and several academic centers have published similar protocols in case reports [8].

The Broader Clinical Dilemma

Osteoporosis in women of reproductive age is uncommon but not rare. Secondary causes include glucocorticoid therapy, anorexia nervosa, osteogenesis imperfecta, inflammatory bowel disease, and hypogonadism. When these patients develop fragility fractures, the pressure to treat pharmacologically is real.

The FDA labeling for every bisphosphonate includes the theoretical warning about bone-stored drug release during future pregnancies. This creates clinical tension: treat the fracture risk now and accept an undefined future reproductive risk, or defer treatment and accept ongoing fracture risk.

No guideline resolves this tension definitively. The Endocrine Society recommends that "women of childbearing potential should be counseled about the theoretical risks of bisphosphonate use and pregnancy" and that "reliable contraception should be used during therapy" [9]. That language places the decision squarely in the shared decision-making space between clinician and patient.

What the data support: alendronate is effective for fracture reduction. It carries a theoretical but unproven risk in pregnancy. Human case reports of inadvertent exposure are reassuring. And no washout period eliminates the bone-stored drug.

Clinicians prescribing alendronate to women of childbearing age should document a pregnancy test before starting therapy, confirm reliable contraception, and discuss the planned duration of treatment with a clear endpoint for discontinuation before conception.